Available to mentor
My career is dedicated to reducing cancer’s burden on patients through translational research and collaborative clinical trials. My clinical and research interests are primarily in head and neck cancer and early-stage therapeutics. These interests stem from the remarkable heterogeneity tumor biology and patient outcomes within a single disease entity, paired with often ineffective therapeutics. My research has focused on development of novel therapeutics for advanced head and neck cancer, biomarker development, and treatment de-escalation strategies in patients with low-risk human papillomavirus related oropharyngeal cancer. My career began by studying small molecule inhibitors in metastatic head and neck cancer which led to development of numerous funded multi-institution investigator initiated clinical trials as a PI. Development of these trials has equipped me with the necessary administrative skills needed for collaborative science including multi-institutional communication, budgeting, and regulatory management. I am the PI of a pivotal multisite investigator-initiated registration trial evaluating MDM-2 inhibition in metastatic salivary gland cancer as well as a co-PI of the NCI iMATCH Feasibility Study S2101 investigating biomarker stratified treatment of advanced solid tumors. Given my research experience, involvement with the head and neck community, and translational research I was appointed to the NCI Recurrent/Metastatic Head and Neck Task Force. In the Spring of 2020, I was also appointed as Co-Director of the University of Michigan Experimental Therapeutics/Phase 1 Program.
-
Center MemberRogel Cancer Center
1) Novel therapeutics and treatment strategies for advanced / metastatic diseases including head and neck cancer.
2) Biomarker development in head and neck squamous cell carcinoma.
3) Tumor immune microenvironment modulation in advanced head and neck cancer.
-
Ferrarotto R, Swiecicki PL, Zandberg DP, Baiocchi RA, Wesolowski R, Rodriguez CP, McKean M, Kang H, Monga V, Nath R, Palmisiano N, Babbar N, Sun W, Hanna GJ. Oral Oncol, 2024 Feb; 149: 106634Journal ArticlePRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study.
DOI:10.1016/j.oraloncology.2023.106634 PMID: 38118249 -
Swiecicki P. 2024 Jan 24;PresentationDevelopment of Biomarker Directed Clinical Trials
-
Swiecicki P. 2024 Jan 16;PresentationResearch Advances in Head and Neck Cancer
-
Wytiaz VA, Swiecicki P. JCO Oncol Pract, 2024 Jan; 20 (1): 15 - 18.Journal ArticleDoublet Therapy: Two Narrative Accounts of One Life-Changing Decision.
DOI:10.1200/OP.23.00544 PMID: 37967294 -
Bhambhani C, Kang Q, Hovelson DH, Sandford E, Olesnavich M, Dermody SM, Wolfgang J, Tuck KL, Brummel C, Bhangale AD, He K, Gutierrez MG, Lindstrom RH, Liu C-J, Tuck M, Kandarpa M, Mierzwa M, Casper K, Prince ME, Krauss JC, Talpaz M, Henry NL, Giraldez MD, Ramnath N, Tomlins SA, Swiecicki PL, Brenner JC, Tewari M. JCI Insight, 2024 Feb 8; 9 (6):Journal ArticlectDNA transiting into urine is ultrashort and facilitates noninvasive liquid biopsy of HPV+ oropharyngeal cancer.
DOI:10.1172/jci.insight.177759 PMID: 38516891 -
Ludwig ML, Michmerhuizen NL, Wang J, Birkeland AC, Majchrowski BK, Nimmagadda S, Zhai J, Bhangale A, Kulkarni A, Jiang H, Swiecicki PL, Brenner JC. Arch Oral Biol, 2023 Dec; 156: 105822Journal ArticleMulti-kinase compensation rescues EGFR knockout in a cell line model of head and neck squamous cell carcinoma.
DOI:10.1016/j.archoralbio.2023.105822 PMID: 37844343 -
Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, Meier F, Su YB, Swiecicki PL, Atlas J, Geiger JL, Hauschild A, Choe JH, Hughes BGM, Schadendorf D, Patel VA, Homsi J, Taube JM, Lim AM, Ferrarotto R, Yoo S-Y, Mathias M, Han H, Seebach F, Lowy I, Fury MG, Rischin D. Lancet Oncol, 2023 Nov; 24 (11): 1196 - 1205.Journal ArticleNeoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.
DOI:10.1016/S1470-2045(23)00459-X PMID: 37875144 -
Swiecicki P. 2023 Oct 30;PresentationDeveloping and Conducting Interventional Clinical Trials